title: Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant.
authors.affiliation: Stanford University , Stanford, CA , USA.
authors.forename: Sally
authors.initials: S
authors.lastname: Arai
authors.forename: Michelle
authors.initials: M
authors.lastname: Fanale
authors.forename: Sven
authors.initials: S
authors.lastname: DeVos
authors.forename: Andreas
authors.initials: A
authors.lastname: Engert
authors.forename: Tim
authors.initials: T
authors.lastname: Illidge
authors.forename: Peter
authors.initials: P
authors.lastname: Borchmann
authors.forename: Anas
authors.initials: A
authors.lastname: Younes
authors.forename: Franck
authors.initials: F
authors.lastname: Morschhauser
authors.forename: Alex
authors.initials: A
authors.lastname: McMillan
authors.forename: Sandra J
authors.initials: SJ
authors.lastname: Horning
mesh_terms: D018450:Disease Progression; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000401:mortality / Q000628:therapy*; D006801:Humans; D012008:Recurrence; D014182:Transplantation, Autologous